Echo MS: High throughput screening with a potential of 3 samples per second

Volker Kruft, Sciex, Darmstadt, Germany

Pramlintide acetate (SYMLINTM) is a synthetic analogue of the human hormone amylin developed as an adjunctive therapy for patients with type 1 and 2 diabetes. With nearing patent expiry dates, and recent research indicating a role for amylin in Alzheimer’s Disease models, interest in amylin and amylin agonists is rising.

Hydrophobic peptides such as pramlintide often suffer from non-specific binding (adsorption) to any labware samples come into contact with (plates, pipette tips, etc…). This can make method development difficult as it can lead to poor recovery, loss of analyte, and poor limits of detection. This work describes optimization and development of a selective sample preparation strategy and LC-MS/MS analysis to achieve LLOQs of 25 pg/mL from 100 μL of serum.

---

Abstract Reference & Short Personal Biography of Presenting Author

Volker Kruft received his PhD from the Max-Planck-Institute of Molecular Genetics under the guidance of Prof. H.-G. Wittmann, working on structure-function relationships of the prokaryotic ribosome. He joined Sciex in 1993 as a product specialist for protein analysis. Since then, he has held various positions at Sciex in support and technical marketing. Currently he holds the position of Senior Business Development Manager for the high growth regions in Africa, Middle East and Eastern Europe/Russia.